OncoMatch/Ovarian Cancer/BRCA1
Ovarian CancerBRCA1 Clinical Trials
Germline and somatic BRCA1 pathogenic variants are present in approximately 15–20% of high-grade serous ovarian carcinoma and define the most sensitive subgroup for PARP inhibitor therapy. Olaparib, niraparib, and rucaparib are FDA-approved as maintenance therapy for BRCA-mutated ovarian cancer across multiple settings. Trials investigate PARP inhibitor combinations with VEGF pathway agents (bevacizumab) and ATR/WEE1 inhibitors, and PARP inhibitor retreatment strategies after resistance.
Top recruiting BRCA1 Ovarian Cancer trials
Ranked by phase and US site count. See all 18 trials matched to your profile →
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Alexander B Olawaiye, MD
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers
Aurigene Discovery Technologies Limited
Browse other molecular targets with active Ovarian Cancer trials.